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A B S T R A C T
Background
Human immunodeficiency virus (HIV) continues to be a leading cause of morbidity and mortality, particularly in sub-Saharan Africa.
Although antiretroviral drugs have helped to improve the quality of life and life expectancy of HIV-positive individuals, there is still a
need to explore other interventions that will help to further reduce the disease burden. One potential strategy is the use of interleukin-
2 (IL-2) in combination with antiretroviral therapy (ART). IL-2 is a cytokine that regulates the proliferation and differentiation of
lymphocytes and may help to boost the immune system.
Objectives
To assess the effects of interleukin-2 (IL-2) as an adjunct to antiretroviral therapy for HIV-positive adults.
Search methods
We searched the following sources up to 26 May 2016: the Cochrane Central Register of Controlled Trials (CENTRAL), published
in the Cochrane Library; MEDLINE; Embase; the Web of Science; LILACS; the World Health Organization (WHO) International
Clinical Trial Registry Platform (ICTRP); and ClinicalTrials.gov. We also checked conference abstracts, contacted experts and relevant
organizations in the field, and checked the reference list of all studies identified by the above methods for any other potentially eligible
studies.
Selection criteria
Randomized controlled trials (RCTs) that evaluated the effects of IL-2 as an adjunct to ART in reducing the morbidity and mortality
in HIV-positive adults.
Data collection and analysis
Two review authors independently screened records and selected trials that met the inclusion criteria, extracted data, and assessed the
risk of bias in the included trials. Where possible, we compared the effects of interventions using risk ratios (RR), and presented them
with 95% confidence intervals (CI). We assessed the overall certainty of the evidence using the GRADE approach.
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Main results
Following a comprehensive literature search up to 26 May 2016, we identified 25 eligible trials. The interventions involved the use of
IL-2 in combination with ART compared with ART alone. There was no difference in mortality apparent between the IL-2 group and
the ART alone group (RR 0.97, 95% CI 0.80 to 1.17; 6 trials, 6565 participants, high certainty evidence). Seventeen of 21 trials reported
an increase in the CD4 cell count with the use of IL-2 compared to control using different measures (21 trials, 7600 participants).
Overall, there was little or no difference in the proportion of participants with a viral load of less than 50 cells/mL or less than 500
cells/mL by the end of the trials (RR 0.97, 95% CI 0.81 to 1.15; 5 trials, 805 participants, high certainty evidence) and (RR 0.96,
95% CI 0.82 to 1.12; 4 trials, 5929 participants, high certainty evidence) respectively. Overall there may be little or no difference in
the occurrence of opportunistic infections (RR 0.79, 95% CI 0.55 to 1.13; 7 trials, 6141 participants, low certainty evidence). There
was probably an increase in grade 3 or 4 adverse events (RR 1.47, 95% CI 1.10 to 1.96; 6 trials, 6291 participants, moderate certainty
evidence). None of the included trials reported adherence.
Authors’ conclusions
There is high certainty evidence that IL-2 in combination with ART increases the CD4 cell count in HIV-positive adults. However,
IL-2 does not confer any significant benefit in mortality, there is probably no difference in the incidence of opportunistic infections,
and there is probably an increase in grade 3 or 4 adverse effects. Our findings do not support the use of IL-2 as an adjunct to ART in
HIV-positive adults. Based on our findings, further trials are not justified.
P L A I N L A N G U A G E S U M M A R Y
Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
Why did we do this review?
HIV is still a major cause of death worldwide, particularly in Africa. HIV multiplies in the blood and damages the immune system.
Therefore if HIV-positive, one is more vulnerable to contract infections. The current drug treatment, antiretroviral therapy (ART),
stops the virus from multiplying thereby allowing the body’s immune system to recover. Interleukin- 2 (IL-2) is a protein in the body
which helps the process of multiplication of white blood cells which are the cells that fight infections. Although IL-2 increases the
amount of white cells we do not know if by increasing these we can add additional benefits to the use of ART alone. The aim of this
Cochrane Review was to find out if using an extra treatment with antiretroviral therapy (ART), namely IL-2, compared to using ART
alone can reduce illness and death in HIV-positive adults.
Key messages
We found that IL-2 causes an increase in the CD4 immune cells (high certainty evidence). However, there is no difference in important
effects such as death and other infections (high certainty evidence). There is probably an increase in side-effects for those people using
IL-2 (moderate certainty evidence). Our findings do not support further use of IL-2 as an add-on treatment to ART in HIV-positive
adults.
Main results
After conducting a comprehensive search on 26 May 2016, we included 25 eligible trials conducted in six countries. There was no
difference in the number of deaths between the IL-2 group and those that got ART alone (6 trials, 665 participants, high certainty
evidence). Seventeen of 21 trials reported an increase in the CD4 cell count with the use of IL-2 compared to ART alone using different
measures. Overall, there was no difference in the proportion of participants with a suppressed viral load of less than 50 cells/mL (5
trials, 805 participants, high certainty evidence) or less than 500 cells/mL by the end of the trials (4 trials, 5029 participants, high
certainty evidence). Overall there may be little or no difference in the incidence of opportunistic infections (7 trials, 6141 participants,
low certainty evidence). There was probably an increase in grade 3 or 4 adverse events (6 trials, 6291 participants, moderate certainty
evidence). None of the included trials reported on adherence.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interleukin-2 compared to control for HIV-positive adults
Patient or population: HIV-posit ive adults
Settings: high- and middle-income sett ings
Intervention: interleukin-2 (IL-2) plus ant iretroviral therapy (ART)
Comparison: ART alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Control IL-2
All-cause mortality 60 per 1000 58 per 1000
(48 to 70)
RR 0.97
(0.80 to 1.17)
6565
(6 trials)
⊕⊕⊕⊕
high
There is lit t le or no ef -
fect on all cause mor-
tality
CD4 cell count Tended to increase in all but one study 7600
(21 trials)
- Tended to increase in
all but one study
HIV RNA levels less
than 50 cells/ mL
636 per 1000 617 per 1000
(515 to 732)
RR 0.97
(0.81 to 1.15)
805
(5 trials)
⊕⊕⊕⊕
high
There is lit t le or no ef -
fect on viral suppres-
sion
HIV RNA levels less
than 500 cells/ mL
81 per 1000 77 per 1000
(66 to 90)
RR 0.96
(0.82 to 1.12)
5929
(4 trials)
⊕⊕⊕⊕
high
Opportunist ic
infect ions
46 per 1000 39 per 1000
(26 to 54)
RR 0.79
(0.55 to 1.13)
6141
(7 trials)
⊕⊕©©
low1
There may be lit t le or no
ef fect on opportunist ic
infect ions
Adverse events (grade
3 or 4)
197 per 1000 242 per 1000
(193 to 303)
RR 1.47
(1.10 to 1.96)
6291
(6 trials)
⊕⊕⊕©
moderate2
There is probably an
increase in adverse
events
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* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relat ive ef fect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1Downgraded by 2 for imprecision due to low event rate result ing in a wide 95%CI is wide. The overall meta-analysis remains
underpowered to conf ident ly exclude ef fects.
2Downgraded by 1 for imprecision.
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B A C K G R O U N D
Description of the condition
Human immunodeficiency virus (HIV) continues to be a major
cause of morbidity and mortality globally (UNAIDS 2016). In
2015 there were 2.1 million people newly diagnosed as HIV-pos-
itive with almost half of those from Southern and Eastern Africa
(UNAIDS 2016). In addition to the decrease in life expectancy
caused by the disease, there are substantial health costs that may
impact on the economy of affected countries. This has all led to
strategic efforts by world leaders and researchers to discover effec-
tive treatments for the condition and thus curtail loss of life and
the related social and economic burden (UNAIDS 2016).
HIV harms the body’s immune system, particularly the CD4 lym-
phocytes. It destroys the host immune system, making it suscep-
tible to opportunistic infections (Grimwade 2009; Harari 2004).
Though various interventions have helped to improve the quality
of life and life expectancy of HIV-positive individuals, interven-
tions are needed that will alleviate the effects of the disease by
restoring the immune system (Harari 2004). For instance, follow-
ing the introduction of antiretroviral therapy (ART) including at
least three antiretroviral agents, the treatment of HIV infection is
highly potent and fairly well tolerated but not without limitations
(Nachega 2011). ART, which is currently the mainstay of treat-
ment, inhibits viral replication and does not reconstitute the im-
mune system directly (Blankson 2000; Piliero 2003). Many HIV-
positive adults do not achieve normal CD4 counts despite sup-
pressing viral replication (Pett 2010).
Long-term ART use is associated with drug-resistant HIV strains,
as well as cumulative drug-related toxicities, including abnormali-
ties in substrate metabolism (Piliero 2003). In addition, prolonged
ART exposure may result in adherence fatigue and increased mor-
bidity. This has encouraged the exploration of novel strategies to
reduce the infection by augmenting the immune system and if pos-
sible completely reconstituting the immune system (Horn 2002).
One such novel potential strategy has been the use of interleukin-
2 (IL-2) as an adjunct with ART (Horn 2002).
Description of the intervention
IL-2 is a cytokine that regulates the proliferation and differentia-
tion of lymphocytes. Cytokines are immunological proteins pro-
duced by lymphocytes which work to expand the pool of im-
munological cells and mobilize latent reservoirs of such cells in
people with HIV and other infections (Pett 2001). IL-2 is a T-
cell growth factor produced predominantly by CD4+ T-cells(Pett
2001). Its production is decreased in HIV-positive participants
(Abrams 2009). A synthetic version of the protein has been pro-
duced as proleukin. It is an important factor in the proliferation
of CD4 T lymphocytes, which is a major target of HIV (Pett
2010). It is also useful in the differentiation of CD4 and CD8
cells, natural killer cells, and macrophages (Horn 2002). These
cells are depleted in HIV-positive participants, and therefore there
has been this interest in the use of IL-2 as an adjuvant therapy in
the treatment of HIV-positive individuals (Horn 2002). The low
dose formulation of proleukin is rarely known to cause side effects
and appears to be well-tolerated (Horn 2002). Earlier studies re-
ported that, by helping the reconstitution of the immune system,
IL-2 may help to defer the commencement of ART in certain
participants by up to 48 weeks (Molina 2007). However, little is
known about its interaction with ART and the potential toxicities
in adults, children, and unborn babies (Horn 2002).
How the intervention might work
IL-2 may work by increasing the CD4 cell count and therefore
assisting to reconstitute the immune system, and help in the con-
trol of viral replication thereby boosting the effect of ART (Horn
2002). By priming the immune system it might help protect it
from the damage caused by HIV and lead to lower susceptibility
to opportunistic infections (Horn 2002).
Why it is important to do this review
If there is proven benefit of using IL-2 as an adjunct in terms of
decreased viral load and adverse effects, increased CD4 counts,
and other patient-related important outcomes, there will be value
in introducing the use of IL-2 more systematically as a treatment
adjunct aiming for an overall improvement in morbidity and mor-
tality. This review aims to summarize the available evidence from
randomized controlled trials (RCTs) on the use of IL-2 as an ad-
junct to ART in the treatment of HIV-positive participants.
O B J E C T I V E S
To assess the effects of interleukin-2 (IL-2) as an adjunct to an-
tiretroviral therapy (ART) for HIV-positive adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
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Types of participants
Adults who were 18 years old and above, diagnosed as seropositive
for HIV on finger prick or laboratory blood testing and eligible to
receive antiretroviral treatment (ART).
These included ART-naive (no prior ART exposure) and ART-
experienced (previously treated or currently on ART) participants.
The safety of interleukin-2 (IL-2) in children is not yet proven.
Types of interventions
IL-2 and any combination of ART.
Variations of interest included IL-2 co-administered with an-
tiretroviral monotherapy or with dual therapy or with the standard
recommended three drug regimens.
We included any dose of IL-2 for this review.
Types of outcome measures
Primary outcomes
• All-cause mortality.
Secondary outcomes
• Change in CD4 cell count.
• Proportion of participants with undetectable viral load at
any time point after initiation of IL-2.
• Opportunistic infections.
• Adherence (as measured by the trial authors).
• Adverse events.
Search methods for identification of studies
Electronic searches
We formulated a comprehensive and exhaustive search strategy in
order to identify all relevant studies regardless of language or pub-
lication status (published, unpublished, in press, and in progress).
Journals and trial databases
We searched the following electronic databases from 1980 up to
26 May 2016.
• The Cochrane Central Register of Controlled Trials
(CENTRAL), published in the Cochrane Library (Appendix 1).
• MEDLINE (Appendix 2).
• Embase (Appendix 3).
Along with MeSH terms and relevant keywords, we used the
Cochrane Highly Sensitive Search Strategy for identifying reports
of RCTs in MEDLINE (Higgins 2008a). We also searched refer-
ences of included studies for other potentially relevant studies. Us-
ing a variety of relevant terms, we also searched ClinicalTrials.gov
(www.clinicaltrials.gov; Appendix 4) and the World Health Or-
ganization International Clinical Trials Registry Platform (WHO
ICTRP) (http://apps.who.int/trialsearch/) for any ongoing trials.
Searching other resources
Conference abstract databases
We planned to search Aegis archive of HIV/AIDS conference ab-
stracts (www.aegis.org). However, this database is no longer func-
tional and was not searched.
We did search the CROI and International AIDS Society web-
sites for abstracts presented at conferences subsequent to those
listed above using different combinations of relevant search terms,
such as antiretroviral, interleukin-2, HIV, viral load, therapy, CD4
count, and other terms in combination. We contacted experts and
relevant organizations in the field to identify any other potentially
eligible studies, including unpublished and ongoing trials.
Data collection and analysis
Selection of studies
Two review authors (JO andCO) independently screened the titles
and abstracts of the literature search results to identify potentially
eligible studies. We resolved any discrepancies through discussion.
We obtained the full-text articles of all potentially eligible articles
in order to formally assess eligibility using the prespecified eligi-
bility criteria. If there was ambiguity we sought clarification from
the study authors. We listed all excluded studies and their reasons
for exclusion in a ’Characteristics of excluded studies’ table. We
also presented the study selection process in a PRISMA diagram.
Data extraction and management
Two review authors (JO and CO) independently extracted data
from the included trials using a detailed data extraction form. We
extracted the following information.
• Study details: citation, start and end dates, location, study
design, and details.
• Participant details: study population eligibility (inclusion
and exclusion) criteria, ages, population size, and attrition rate.
• Details about the interventions: dose, duration of
treatment, concomitant antiretroviral treatment (ART) regimens.
• Details of the outcomes: CD4 cell count, viral load, death,
adverse effects, and adherence.
For each dichotomous outcome, we extracted the number of par-
ticipants experiencing the event and the number of participants in
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each treatment group. For each continuous outcome we extracted
the mean or geometric mean values and standard deviations (SDs)
(or information to estimate the SDs) for each treatment group,
together with the numbers of participants in each group. We also
extracted the median and range values if these were reported in
place of mean and SDs values.
Assessment of risk of bias in included studies
Two review authors (JO and CO) performed the ’Risk of bias’ as-
sessments independently using the Cochrane ’Risk of bias’ assess-
ment tool (Higgins 2008b). The Cochrane approach assesses risk
of bias in individual studies across the following six domains: se-
quence generation, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting, and other potential
biases.
We resolved any differences in opinion through discussion. We
presented the ’Risk of bias’ assessments for individual trials in the
’Risk of bias’ tables, and also in a ’Risk of bias’ summary and ’Risk
of bias’ graph.
Measures of treatment effect
For dichotomous outcomes, we used risk ratios (RRs) to measure
treatment effect. For continuous outcomes, we presented themean
or median and SD values or ranges. We presented RRs and mean
differences with 95% confidence intervals (CIs).
Unit of analysis issues
All included trials were RCTs and we analysed the data at the level
of the individual.
Dealing with missing data
We did not apply any imputation measures for missing data as
there were no missing data. we planned to contact authors for
missing data, but this was not required.
Assessment of heterogeneity
We assessed statistical heterogeneity by visually inspecting the for-
est plots to detect overlapping confidence intervals, applying the
Chi2 test (P value < 0.10 considered statistically significant), and
also by using the I2 test statistic to evaluate the degree of hetero-
geneity.
Assessment of reporting biases
Funnel plots describe the relationship between the standard error
and the effect size and provide a graphic display of potential re-
porting bias. We had planned to evaluate reporting bias by assess-
ing the symmetry of a funnel plot. However, as the recommended
10 study minimum was not met for any of the outcomes, we did
not proceed with the funnel plot assessment.
Data synthesis
We analysed data using Review Manager 5 (RevMan 5) software
(Review Manager 5), and conducted meta-analysis using the ran-
dom-effectsmodel.We assessed the certainty of the evidence across
each outcome measure by using the GRADE approach. The cer-
tainty rating across studies has four levels: high, moderate, low, or
very low certainty but can be downgraded after assessment of five
criteria: risk of bias, consistency, indirectness, imprecision, and
publication bias. Similarly, observational studies are initially cate-
gorized as low certainty and can be downgraded by these same cri-
teria. In exceptional circumstances they may be upgraded by three
further criteria: large effect size, all plausible confounders would
act to reduce the effect size, and evidence of a dose-response effect
(Guyatt 2008)
Subgroup analysis and investigation of heterogeneity
We performed a subgroup analysis based on whether the partici-
pants were ART experienced or ART naive.
Sensitivity analysis
Several studies had unclear risk of bias due to unclear reporting
on allocation concealment, but this was not adequate to prompt
a sensitivity analysis based on the trial quality.
R E S U L T S
Description of studies
Results of the search
We performed electronic literature searches up to 26 May 2016.
We identified a total of 1007 records, which we screened by ti-
tle/abstract. We identified 35 potentially eligible studies and ob-
tained the full-text articles of these studies. We excluded 10 stud-
ies, which we listed along with their reasons for exclusion in the
’Characteristics of excluded studies’ table. Twenty-five trials met
the inclusion criteria of the review. We have presented the study
selection process in a PRISMA flow diagram (Figure 1).
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Figure 1. Study flow diagram
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Included studies
See the ’Characteristics of included studies’ and Table 1, which
further describe the populations and interventions in the included
trials.
Study design and setting
We included 25 parallel-design RCTs in the review (Abrams 2002;
Abrams 2009a; Abrams 2009b; Amendola 2000; Caggiari 2001;
Carr 1998; Davey 2000; de Boer 2003; Dybul 2002; Hengge
1998; Katlama 2002; Kelleher 1998; Kovacs 1996; Lalezari 2000;
Levy 1999; Levy 2003; Losso 2000; Marchetti 2002; Marchetti
2004; Mitsuyasu 2007; Ruxrungtham 2000; Stellbrink 2002;
Tambussi 2001; Tavel 2003; Vogler 2004).
Eleven trials were conducted in academic centres in the USA (
Abrams 2002; Davey 2000; Dybul 2002; de Boer 2003; Abrams
2009a; Abrams 2009b; Kovacs 1996; Lalezari 2000; Mitsuyasu
2007; Tavel 2003; Vogler 2004). The other 14 included trials
were conducted inArgentina (Losso 2000), France (Katlama 2002;
Levy 1999; Levy 2003), Italy (Amendola 2000; Caggiari 2001;
Marchetti 2002;Marchetti 2004; Tambussi 2001), Australia (Carr
1998; Kelleher 1998), Germany (Hengge 1998; Stellbrink 2002),
and Thailand (Ruxrungtham 2000).
Participants
All participants were HIV-positive adults either ART experienced
or who were commenced on ART during the trial, with CD4
cell counts of at least 50 cells/mm³. The number of participants
per trial ranged from nine participants (Dybul 2002), to 4111
participants (Abrams 2009a).
Interventions
In all included trials, participants in the intervention group re-
ceived IL-2 and ART, while those in the control group received
ART alone. The dose of IL-2 and the ART regimen varied across
the included trials. Some trials compared doses of either 4.5 miu
of IL-2 , 7.5 miu of IL-2 with ART, or different subgroups of
both doses with the control group (Abrams 2002; Abrams 2009a;
Abrams 2009b; Davey 2000). Some trials had three trial arms that
compared different routes of administration, including subcuta-
neous versus intravenous administration with the control group
(ARTalone) (Carr 1998;Mitsuyasu 2007; Tambussi 2001).Other
included trials had three trial arms that compared IL-2, a control
group, and different modified forms of IL-2, such as polyethy-
lene glycol (PEG) modified IL-2 (Carr 1998; Kelleher 1998;
Levy 1999), and granulocyte stimulating factor-modified IL-2
(Amendola 2000), and prednisone-modified IL-2 (Vogler 2004).
Outcomes
Of the outcomes of interest in this Cochrane Review, the included
trials reported the following outcomes: all-cause mortality, change
in CD4 cell, viral load, opportunistic infections, and adverse ef-
fects. However, none of the included trials reported on adherence.
Excluded studies
After considering the full-text articles, we excluded 10 poten-
tially eligible studies that did not meet our inclusion criteria.
We have provided the reasons for excluding these trials in the
’Characteristics of excluded studies’ table.
Risk of bias in included studies
We have provided a graphical summary of the ’Risk of bias’ assess-
ment results (Figure 2; Figure 3).
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included trials
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included trial
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Allocation
Random sequence generation
There was adequate sequence generation in 11 of the 25 included
trials (Abrams 2002; Abrams 2009a; Abrams 2009b; Davey 2000;
de Boer 2003; Katlama 2002; Lalezari 2000; Levy 2003; Losso
2000; Mitsuyasu 2007; Ruxrungtham 2000). There was high risk
of selection bias inHengge 1998. The remaining 13 included trials
poorly reported the method of sequence generation.
Allocation concealment
More than half of included studies did not report allocation con-
cealment clearly and were judged as having unclear risk of bias.
One study, Hengge 1998, had high risk of allocation concealment
bias due to the manner in which participant selection was con-
ducted. .
Blinding
The included trials were open label trials with no blinding of
participants. However, all of the reported outcome measures are
objective. Therefore we judged each of the included trials as at low
risk of bias regarding blinding.
Incomplete outcome data
We considered the following trials to have a low risk of attrition
bias with low or minimal loss to follow-up: Abrams 2002; Abrams
2009a; Abrams 2009b; Carr 1998; Davey 2000; de Boer 2003;
Hengge 1998; Katlama 2002; Kelleher 1998; Kovacs 1996; Levy
1999; Levy 2003; Losso 2000; Marchetti 2002; Marchetti 2004;
Stellbrink 2002; Tambussi 2001; andVogler 2004. There was high
risk of attrition bias in Lalezari 2000 and Mitsuyasu 2007. Five
trials had unclear risk of attrition bias (Amendola 2000; Caggiari
2001; Dybul 2002; Ruxrungtham 2000; Tavel 2003).
Selective reporting
All included trials were at low risk of selective reporting bias. The
trials reported all outcomes that they described in the methods in
the results.
Other potential sources of bias
We identified other potential sources of bias in the following three
trials (Carr 1998; Losso 2000; Tambussi 2001). In Carr 1998,
there was potential for both detection bias or performance bias
due to the fact that the IL-2 group were hospitalized for five to six
days longer than the control group. However, as the outcomes re-
ported are considered objective (i.e. CD4 count and viral load) the
potential risk is probably low. Losso 2000 had more monitoring
in the IL-2 group than in the control group, which caused a po-
tential for detection bias and performance bias since some adverse
effects could be subjective. There was a high risk of performance
bias in Tambussi 2001 due to differential treatment. Participants
who were randomized to the continuous intravenous high dose
and subcutaneous high dose groups received the first two cycles of
IL-2 as inpatients and the following cycles on an outpatient basis,
whereas participants in the low dose and control groups were fol-
lowed up as outpatients from the beginning of the trial.
Effects of interventions
See: Summary of findings for the main comparison ’Summary
of findings’ table 1
See Summary of findings for the main comparison.
Primary outcomes
All-cause mortality
Eight trials reported on all-cause mortality (Abrams 2002; Abrams
2009a; Abrams 2009b; Kovacs 1996; Levy 1999; Losso 2000;
Mitsuyasu 2007; Vogler 2004). Trials reported mortality at six
months (Vogler 2004), 12 months (Abrams 2002), 13 months
(Levy 1999), 14 months (Kovacs 1996), 20 months (Mitsuyasu
2007), and seven years (Abrams 2009b; Abrams 2009a). Levy
1999 and Mitsuyasu 2007 had more than two trial arms, which
we did not include in the pooled analysis. Therefore, we pooled re-
sults from six trials (Abrams 2002; Abrams 2009a; Abrams 2009b;
Kovacs 1996; Losso 2000; Vogler 2004) (risk ratio (RR) 0.97, 95%
confidence interval (CI) 0.80 to 1.17; 6 trials, 6565 participants,
high certainty evidence; Analysis 1.1; Figure 4). There was no sig-
nificant difference in the test for subgroup differences looking at
ART experienced participants and others (ART naive or experi-
enced or unclear ART status). We also did not find any significant
subgroup differences with trials that reported the outcome at seven
years and those that reported the outcome at less than 24 months.
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Figure 4.
Secondary outcomes
Change in CD4 cell count
Twenty-one trials reported on change in CD4 cell count: (Abrams
2002; Abrams 2009a; Abrams 2009b; Amendola 2000;Carr 1998;
Davey 2000; de Boer 2003; Dybul 2002; Hengge 1998; Katlama
2002; Kovacs 1996; Lalezari 2000; Levy 1999; Levy 2003; Losso
2000; Marchetti 2002; Mitsuyasu 2007; Tambussi 2001; Tavel
2003; Ruxrungtham 2000; Vogler 2004).
We did not pool the results because the included trials reported
either means or median values differently (see Table 2 which de-
scribes the different reporting on CD4 count changes by the in-
cluded trials).
Significant increase in CD4 cell count with IL-2
Fifteen trials reported a significant increase in CD4 cell count
in the group assigned to IL-2 treatment (Abrams 2002; Carr
1998; Davey 2000; de Boer 2003; Hengge 1998; Katlama 2002;
Kovacs 1996; Lalezari 2000; Levy 1999; Levy 2003; Losso 2000;
Marchetti 2002; Mitsuyasu 2007; Tavel 2003; Ruxrungtham
2000).
Increase in CD4 cell count but statistical significance not
reported
Five trials provided results for a relative increase in CD4 count in
the groups receiving IL-2. Abrams 2009a reported this outcome
at seven years; Abrams 2009b and Amendola 2000 reported at
six months; Dybul 2002 and Tambussi 2001 reported this at 84
weeks. However, these trials did not provide further details of
whether the difference was statistically significant.
No significant increase in CD4 cell count
Two trials reported that there was no significant difference in the
CD4 cell count between groups over 24 weeks, Ruxrungtham
2000 andVogler 2004; however in theRuxrungtham2000 trial the
lack of difference dependedon the dosing of IL-2with higher doses
resulting in a significant difference in a dose-response manner.
Proportion of participants with undetectable viral load at
any time point
Plasma viral load less than 50 copies/mL
Seven trials reported on viral load of less than 50 copies/mL
(Abrams 2002; Davey 2000; Lalezari 2000; Levy 2003; Marchetti
2002; Mitsuyasu 2007; Tavel 2003). None of the included trials
found any significant difference between the two groups irrespec-
tive of the time when the viral load was measured. Overall, in the
pooled analysis, there was no significant difference in the propor-
tion of participants with a viral load of less than 50 copies/mL by
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the end of the trials (RR 0.97, 95% CI 0.81 to 1.15; 5 trials, 805
participants, high certainty evidence; Analysis 1.2; Figure 5).
Figure 5.
Plasma viral load level less than 500 copies/mL
Four trials reported on plasma viral load of less that 500 copies/mL
(Abrams 2009a; Abrams 2009b; Levy 1999; Losso 2000). None
of the included trials found any significant difference between the
two groups in viral load of less than 500 copies/mL irrespective of
the time when the viral load was measured. The overall results did
not show any significant difference in the two groups (RR 0.96,
95% CI 0.82 to 1.12; 4 trials, 5929 participants, high certainty
evidence; Analysis 1.3; Figure 6).
Figure 6.
Undetectable viral loads
In Amendola 2000, participants in both groups had HIV load
levels below detection limit at the end of the study. Caggiari 2001
reported undetectable viral loads in six out of seven participants
both the IL-2 and ART only group. Carr 1998 did not report
any difference in the mean viral load in any of the study arms.
In Kovacs 1996, there were no significant differences between the
groups in serial measurements of the plasma viral load or p24
antigen concentration during the 12 months of treatment.
Other viral load measurements
Six included trials found no significant difference in viral load
(Hengge 1998; Katlama 2002; Levy 2003; Marchetti 2002;
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Tambussi 2001; Vogler 2004).
Opportunistic infections
Seven included trials reported the incidence of opportunistic infec-
tions (Abrams 2009a; Abrams 2009b; Carr 1998; Hengge 1998;
Katlama 2002; Kovacs 1996; Mitsuyasu 2007). Overall there was
no significant difference between the two groups (RR 0.79, 95%
CI 0.55 to 1.13; 7 trials, 6141 participants, low certainty evidence;
Analysis 1.4; Figure 7).
Figure 7.
Adherence
None of the included trials reported on adherence.
Adverse events
Nine included trials reported on adverse events (Abrams 2009a;
Abrams 2009b; Davey 2000; de Boer 2003; Katlama 2002;
Lalezari 2000; Levy 2003; Marchetti 2002; Tavel 2003).
GRADE 3 or higher adverse events
In Abrams 2009a, a total of 203 participants receiving IL-2 and
186 participants in the control group had a grade 4 adverse event.
In Abrams 2009b, a total of 203/849 participants receiving IL-
2 and 186/846 participants in the control group had a grade 4
adverse event. Davey 2000 reported grade 3 or higher adverse
events in 20/39 participants in the IL-2 group and in 7/43 ad-
verse events in the control group (RR 3.13, 95% CI 1.50 to 6.63).
Lalezari 2000 reported grade 3 adverse events in 10/56 participants
(18%) in the IL-2 group and in 9/59 (15%) of the control group
while grade 4 adverse events were 1 (2%) and 3 (5%) respectively.
Levy 1999 reported that severe adverse effects, such as aspartate
transaminase deficiency, were reported in 2/26 of the participants
in the control group and 16 participants (25%), 2 participants
(5%), and 4 participants (9%), in the subcutaneous, PEG-modi-
fied, and intravenous IL-2 groups respectively. Severe neutropenia
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(less than 1 x 109/mL) was also seen in 2/26 (8%) participants in
the control group and 9 participants (8%), 2 participants (9%),
3 participants (4.5%) in the subcutaneous, PEG-modified, and
intravenous IL-2 groups. Levy 2003 reported that grade 3 or 4
adverse effects were noted in 34/53 participants (64%) in the IL-2
group compared to 12/56 participants (22%) in the control group
(P < 0.001).
In Mitsuyasu 2007, both IL-2 arms were associated with signif-
icantly more grade 3 or 4 clinical toxic effects usually associated
with IL-2 treatment (with values of 30%, 53%, and 67% for 57,
58, and 59 participants) in the ART only, intravenous IL-2 group,
and subcutaneous IL-2 group respectively. Tavel 2003 reported
episodes of severe toxicities, neutropenia, and orthostatic blood
pressure respectively in 2/5 participants compared to 0/4 in the
control participants. Vogler 2004 reported no statistical significant
difference between both groups in grade 3 or worse adverse effects
(P≥ 0.12). By the end of the trial at 24 weeks, two grade 4 events
had occurred: one case of grade 4 hypertriglyceridaemia, one case
of agitation in the ART plus IL-2 group, and none in the con-
trol. Overall there were greater adverse effects in those participants
receiving IL-2 (RR 1.47, 95% CI 1.10 to 1.96; six trials, 6291
participants, moderate certainty evidence; Analysis 1.5; Figure 8).
Figure 8.
GRADE 2 or lower adverse events
In Lalezari 2000, grade 2 or lower adverse events were reported in
43/56 participants in the IL-2 group and in 47/59 of the control
group. Katlama 2002 reported that all participants receiving IL-2
experienced at least one mild-to-moderate side-effect, mainly con-
stitutional symptoms such as fever, fatigue, malaise, and myalgias.
Marchetti 2002 reported lower than grade 3 events in a total of 11
participants. Mild constitutional symptoms, such as fever (grade 1
to 2), fatigue, and myalgia were experienced by 10/12 participants
receiving IL-2, a reversible localized erythematous nodule at the
site of injection was observed in 11/12 participants.
D I S C U S S I O N
Summary of main results
We identified 25 trials that met our inclusion criteria. The number
of participants in the included trials varied from nine to 4111 par-
ticipants. Interleukin-2 (IL-2) doses and the duration of follow-
up varied across the included trials. We judged the risk of bias due
to methodological quality of the included studies to be low. There
was no significant difference in mortality whether IL-2 was added
to the ART regimen or not (high certainty evidence). There was a
significant increase in CD4 cell count in the IL-2 group in most
of the included trials (high certainty evidence). There was no sta-
tistically significant difference between viral load in both groups
for measures less than 50 copies/mL or 500 copies/mL in most
trials (high certainty evidence). IL-2 probably causes an increase in
adverse effects, particularly grade 3 or 4 adverse effects (moder-
ate certainty evidence). Most of the included trials reported similar
adverse events, neutropenia, and myalgia were most commonly
reported. There is probably no difference in the incidence of op-
portunistic infections in the IL-2 and control groups (low certainty
evidence). Adherence was not reported in any of the included trials.
Overall completeness and applicability of
evidence
We conducted a comprehensive search and included all relevant
trials regardless of whether they reported the reviews outcomes
of interest. Most included trials excluded participants who were
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previously on immunomodulators or steroids, or with an autoim-
mune disease, or with malignancy requiring them to be on im-
munomodulators. The trials were conducted in different settings:
including high- and middle-income countries. However, there is
no plausible biological reason why the findings may not be appli-
cable to low-income settings.
Quality of the evidence
We assessed the certainty of the evidence using the GRADE
methodology, and presented the basis for the judgements in a
’Summary of findings’ table. The overall certainty of evidence on
the effects of IL-2 as an adjunct to ART for reducing morbidity
and mortality in HIV-infected adults individuals can be described
as high, which means that we are confident in this result and fur-
ther research is unlikely to change the direction of the effect. This
finding was consistent across all the included trials that reported
on the outcome. In addition, IL-2 increases the CD4 cell count
significantly and there is no difference in the proportion of partic-
ipants with undetectable viral loads (high certainty evidence). IL-
2 probably does not cause any important difference in the rates
of opportunistic infections (low certainty evidence). However, it
probably causes increased grade 3 or 4 adverse effects (moderate
certainty evidence).
Potential biases in the review process
We conducted a comprehensive search to ensure that we identi-
fied all relevant completed or ongoing studies. There were no lan-
guage or publication restrictions. We also reduced the potential
bias in the conduct of this review: two review authors indepen-
dently screened the search output, extracted data, and assessed the
methodological certainty of each included trial.
Agreements and disagreements with other
studies or reviews
The findings of this review are similar to those of a literature review
by Pett 2001, which showed that IL-2 adjunctive therapy can
significantly increase the CD4 pool of HIV-positive participants
compared to ART alone, however it has no significant effect on
viral load, and has an increase in adverse effects, particularly grade
4 adverse effects in some trials and an acceptable adverse effect
profile in others. Pett 2010 concluded that IL-2 adjunctive therapy
confers no clinical benefit on HIV-positive participants and has
no place in the therapeutic treatment of HIV. Three trials that we
included in this Cochrane Review were also included in Pett 2010
(Abrams 2009a; Abrams 2009b; Stellbrink 2002).
The findings of this Cochrane Reviewdiffer from those of a pooled
meta-analysis of three randomized controlled trials (RCTs) by
Emery 2000, which showed a significant decrease in viral load in
participants on IL-2 with ART compared to ART alone. However,
Emery 2000 also showed no significant increase in mortality and
concluded that despite substantial improvement inCD4 cell count
and viral load there was no significant improvement in clinical
outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Interleukin-2 (lL-2) as an adjunct to ART leads to increases in
CD4 cell counts in HIV-infected adults on ART. However, IL-2
(irrespective of the dose or duration) has no important effect on
other clinically important positive outcomes, such as mortality,
viral load reduction, and rates of opportunistic infections, but
probably results in increased adverse effects. Our findings do not
support the use of IL-2 as an adjunct to ART in HIV-infected
adults.
Implications for research
Further RCTs on the use of IL-2 as adjunct to ART in HIV-
infected adults are not justifiable based on the findings of this
Cochrane review. However, further basic research may be helpful
to explore why IL-2 causes increases in CD4 cell count.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abrams 2002
Methods Open-label randomized controlled trial (RCT)
Participants Eligibility criteria
• HIV-positive.
• Adults (18 years or older).
• CD4 cell count of at least 300 cells/mm³.
• Receiving or initiating combination antiretroviral therapy (ART) at the time of
randomization.
Exclusion criteria
• Pregnancy.
• AIDS-defining illness.
• Malignancy requiring chemotherapy.
• Use of systemic corticosteroid, hydroxyurea, or any other immunomodulator
therapy within 4 weeks before randomization.
• Autoimmune disease.
• Breastfeeding.
• Any central nervous system (CNS) abnormality requiring anti-seizure medication.
The trial included a total of 511 (256 in the interleukin group and 255 in the control
group) HIV-1 infected adults
• Most participants were men (88.5%), white (69.3%), and had sex with a person
of the same sex (76.7%).
• Median CD4 cell count at randomization was 536 cells/mm³ (302 to 1591 cells/
mm³).
Interventions Intervention group: intermittent administration of 2 doses (4.5 and 7.5 miu) of subcu-
taneous plus antiretroviral treatment (ART)
Control group: ART alone.
Outcomes • Viral load.
• CD4 cell count.
Notes The trial was conducted in the USA.
Duration of follow-up: minimum of 12 months. Median duration of follow-up was 16.
2 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used permuted block randomiza-
tion with stratification by the CPCRA unit
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Abrams 2002 (Continued)
Allocation concealment (selection bias) Low risk The trial obtained random allocation of
participants by calling the CPCRA Statis-
tical Centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the
outcomes measures are objective and un-
likely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the
outcomes measures are objective and un-
likely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 15% of the participants were ex-
cluded from the final analysis or lost to
follow-up, and it was by intention-to-treat
(ITT) analysis
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing.
Other bias Low risk There was no evidence of bias from other
sources.
Abrams 2009a
Methods Open-label RCT
Participants Eligibility criteria: HIV-infected adult
Exclusion criteria: not specified
Interventions Intervention group: 3 cycles and a dose of 7.5 miu of IL-2 twice daily plus ART
Control group: ART alone .
Outcomes • CD4 cell count.
• Viral load.
• Opportunistic infections.
• Death from any cause.
• Adverse events.
Notes The trial was conducted in the USA. The median duration of follow-up was 7.0 years
Ths trial was funded and sponsored by the National Institute of Allergy and Infectious
Diseases (NIAID)
Risk of bias
Bias Authors’ judgement Support for judgement
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Abrams 2009a (Continued)
Random sequence generation (selection
bias)
Low risk The trial stratified randomization by individual clinical site
Allocation concealment (selection bias) Low risk The central coordinating facility prepared all randomizations
schedules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The analysis was based on an ITT principle and less than 15%
were lost to follow-up
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk There was no evidence of other forms of bias.
Abrams 2009b
Methods Open-label RCT
Participants Eligibility criteria: HIV-positive adults with CD4 cell count between 50 and 299 cells/
mm³
Exclusion criteria: not specified
Interventions Intervention group: 1 cycle of a dose of 4.5 miu twice daily for 5 consecutive days
Control group: ART alone
Outcomes • CD4 cell count.
• Viral load.
• Opportunistic infections.
• Death from any cause.
• Adverse events.
Notes The trial was conducted in the USA. The median duration of follow-up was 7.6 years
The NIAID provided regulatory sponsorship, and Chiron, and subsequently Novartis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial stratified randomization by individual clinical site
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Abrams 2009b (Continued)
Allocation concealment (selection bias) Low risk The central co-ordinating facility prepares all randomization
schedules
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The analysis was based on an ITT principle and less than 15%
were lost to follow-up
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk There was no evidence of other forms of bias.
Amendola 2000
Methods Open-label RCT
Participants 22 HIV-infected adults (12 males and 10 females)
Inclusion criteria
• HIV-infected adults > 18 years of age.
• Asymptomatic.
• CD4 cell count > 400 to 600 cells/mm³.
• Viral load > 5000 copies/mL.
Exclusion criteria
• Prior exposure to antiretrovirals, immunomodulators, corticosteroids.
• Hepatitis B and C infection.
• Patients with autoimmune disease.
Interventions The participants were enrolled in 3 randomized groups.
• Six participants (group 1) were treated with ART (Indinavir 2400 mg/day;
stavudine 60 ± 80 mg/day; lamivudine 300 mg/day).
• Eight participants (group 2) were treated with ART and IL-2 (aldesleukin, 1000
000 U/day ) subcutaneously, 5 days/week at alternative weeks).
• Eight participants (group 3) received granulocyte colony-stimulating factor (G-
CSF; filgrastim, 5 mg/kg per day, for 5 consecutive days) to stimulate hematopoietic
progenitor cell mobilization before starting ART and rIL-2.
All participants were treated with ART for 1 month before receiving differentiated ther-
apies (ART; ART 1rIL-2; (G-CSF) ART 1rIL-2) for an additional 12/24 weeks
Outcomes • CD4 cell count.
• Viral load.
• Level of peripheral mononuclear blood cell apoptosis.
• Expression of CD45RA and CD62L T naive cells and memory cells.
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Amendola 2000 (Continued)
Notes The trial was conducted in Italy.
Duration of follow-up: 24 weeks.
Outcomes were analysed at baseline, 12, and 24 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe whether this was done or not
Allocation concealment (selection bias) Unclear risk The trial authors did not describe whether this was done or not
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk We do not have enough information from the trial to make a
judgement
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk We did not identify any other potential sources of bias.
Caggiari 2001
Methods Paralell single centred RCT
Participants 14 HIV-infected adults
Inclusion criteria
• ART naive.
• CD4 > 200 cells/mm³.
• HIV viraemia > 500 copies/mL.
• No previous IL-2 therapy.
• At least 18 years of age.
• 1000 granulocytes/mm³.
Exclusion criteria
• Abnormal thyroid function and cardiovascular.
• Abnormal pulmonary and central nervous system involvement.
Interventions Intervention group: 6 miu of IL-2 from days 1 to 5 and 8 to 12 of a 28 day cycle for 6
cycles plus ART(2 reverse transcriptase inhibitors and indinavir)
Control group: ART alone
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Caggiari 2001 (Continued)
Outcomes • CD4 cell count.
• Viral load.
Notes This trial was conducted in Italy.
Duration of follow-up: 12 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk There was no mention of the specific method of sequence
generation or randomization but in the discussion section
it was stated that randomization was done to ensure com-
parability of both groups
Allocation concealment (selection bias) Unclear risk There was nomention of the specificmethod of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and not likely to have been influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk We do not have enough information from the study to
make a judgement
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk We did not identify any other potential sources of bias.
Carr 1998
Methods RCT
Participants 115 HIV-infected adults
Inclusion criteria
• HIV-infected adults > 18 years of age.
• CD4 lymphocyte count between 200 and 500 cells/mm³.
• Karnofsky score = 60.
• At least 2 months of continuous antiretroviral therapy (ART) at study initiation.
• No prior IL-2 therapy.
• No AIDS-defining illness.
Exclusion criteria: not specified
26Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Carr 1998 (Continued)
Interventions There were 3 trial arms
• Intravenous IL-2 plus ART, 12,000,000 IU of IL-2 daily for 5 days every eight
weeks (27 participants).
• Subcutaneous PEG IL-2 plus ART, 1,000,000 IU per cycle in equal divided doses
in day 1 and 3 every eight weeks (58 participants).
• ART alone (30 participants).
ART consisted of zidovudine + didanosine + zalcitabine
Outcomes • CD4 cell count.
• CD8 cell count.
• Adverse events.
Notes The trial was conducted in Australia.
Duration of follow-up: 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial not describe the method for sequence generation.
Allocation concealment (selection bias) Unclear risk The trial did not described the method for allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial authors analysed all participants included in the trial
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias High risk There was a high risk of selection bias and detection bias. Par-
ticipants were randomized on a 1:2:1 basis for the continuous
intravenous IL-2, PEG-IL-2 ( Polyethylene glycol ) modified IL-
2, and control groups respectively. The trial authors rationalized
that the unequal randomization allowed for determination of
the maximally tolerated dose significance levels of PEG IL-2 as
well as its efficacy. This was bound to cause selection bias. Sec-
ondly, IL-2 participants were hospitalized the first 5 to 6 days of
the cycle causing possible detection bias
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Davey 2000
Methods Multicentred RCT
Participants Inclusion criteria: HIV-infected adults
Exclusion criteria: not specified
Interventions Intervention: 6 cycles of IL-2, 7.5 miu + ART
Control: ART alone
Outcomes CD4 cell count
Viral load
Adverse events
Notes The trial was conducted in the USA.
Duration of follow-up was 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial randomly assigned participants to treatment groups by
a computer generated block randomization with block sizes of
4 for the first 2 blocks and subsequently block sizes of 2
Allocation concealment (selection bias) Low risk Central randomization by a biostatistician who was not part of
the data analysis
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biostatisticians were blinded from knowing which participants
were in which treatment groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk It is unlikely that there was attrition bias since < 15% withdrew
orwere lost to follow-up. There was no differential loss to follow-
up
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome reporting.
Other bias Low risk There was no evidence of other potential sources of bias.
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de Boer 2003
Methods Multi-centred RCT
Participants Inclusion criteria
• Karnofsky performance score greater than or equal to 70.
• HIV-positive participant aged 18 years and above.
• CD4 cell counts of between 100 to 300 cells/mm³.
• Prior use of stable ART regimen for at least 2 months before the trial.
• No AIDS defining illness except kaposi’s Sarcoma or pneumocystis jirovecii
pneumonia.
Exclusion criteria: not specified
Interventions Treatment group: participants received intravenous recombinant IL-2 12 miu/day for 3,
4, or 5 days + ART every 8 weeks for 6 cycles
Control group: ART alone
Outcomes • Change in CD4 cell count.
• Viral load.
• Adverse effects.
• AIDS defining illness.
Notes The trial was conducted in USA. Duration of follow-up was 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk There is likely to be a low risk of selection bias as participants
were assigned in equal proportions of 1 to 4 treatments and
participants were stratified by treatment centre
Allocation concealment (selection bias) Low risk Randomization was done centrally.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial addressed loss to follow-up and was less than 15%.
Selective reporting (reporting bias) Low risk There was no evidence of potential reporting bias from selective
reporting
Other bias Low risk There was no evidence of other potential sources of bias.
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Dybul 2002
Methods RCT
Participants 9 participants
Inclusion criteria
• HIV RNA level of > 500 copies/mL.
• Documented HIV infection of< 6 months with participant already on ART.
• Non-reactive ELISA within 6 months of enrolment.
• participants with a history of symptoms or prior exposure to acute antiretroviral
syndrome and a non reactive western blot within 6 months of enrolment.
• participants with a history of symptoms or prior exposure to acute antiretroviral
syndrome and an indeterminate western blot within 6 months of enrolment.
Exclusion criteria: not specified
Interventions Treatment group: intermittent IL-2 administered subcutaneously in 3 cycles for 5 days
every 8 week plus ART
Control group: ART alone. regimen:
stavudine 30 mg to 40 mg twice daily,
lamivudine 150 mg twice daily, indinavir 800 mg twice daily
Outcomes • CD4 cell count.
• Lymphocyte subsets including CD4+, CD45RO, CD3+, CD8+.
Notes This was a pilot study conducted in the USA. Duration of follow-up: 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not provide any details.
Allocation concealment (selection bias) Unclear risk The trial authors did not provide any details.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes measures
are objective and unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk We do not have enough information from the trial to make a
judgement
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk We did not identify any other potential sources of bias.
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Hengge 1998
Methods This was a prospective RCT
Participants There was a total of 64 participants.
Inclusion criteria
• Adult HIV-positive participants with CD4 count between 200 to 500 cells/mm³.
• Normal haematological, hepatic, biliary, and renal function.
• Had been receiving stable ART (saquinavir, lamivudine, and zidovudine)
Exclusion criteria: not specified
Interventions Treatment group A (22): ART plus subcutaneous IL-2 administered at a dose of 9.6 miu
daily in cycles consisting of 5 days. A total of 5 cycles were given. One cycle was given
every 6 weeks over a period of 52 weeks
Treatment group B (22): ART plus subcutaneous IL-2 administered at a dose of 9.6 miu
daily whenever CD4 counts dropped to below 1.25 fold of individual’s baseline value
Control group: ART alone
participants were followed up for a duration of 12 months
Outcomes • Change in CD4 count.
• Proportion of people with undetectable viral load.
• Opportunistic infections.
• Adverse effects
Notes The trial was conducted in Germany.
Duration of follow-up: 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk There was no true randomization as controls were chosen
from participants fulfilling the inclusion criteria who did
not wish to experience the potentially adverse effects of
lL-2
Secondly, the trial authors did not describe the method
of sequence generation
Allocation concealment (selection bias) High risk There is unlikely to be allocation concealment based on
the support for judgement for sequence generation above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk There is unlikely to have been attrition bias as the trial
excluded less than 15% of the participants
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Hengge 1998 (Continued)
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting of outcomes.
Other bias Low risk There were no other potential sources of bias.
Katlama 2002
Methods Multicentred open label RCT
Participants A total of 72 participants.
Inclusion criteria
• 18 years or older.
• CD4 cells counts 25-200 cells/mm³.
• Viral load of < 1000 copies/mL while receiving ART (2 nucleoside analogues and
1 protease inhibitor (PI)) for 3 months.
Exclusion criteria: participants on cytotoxic chemotherapy or corticosteroids within 3
months prior to the trial
Interventions Intervention: 4.5 miu of IL-2 administered subcutaneously plus ART every 6 weeks for
4 cycles, every 12 hours for 5 days
Control: ART alone
Outcomes • Plasma HIV RNA levels.
• CD4 and CD8 count.
Notes The trial was conducted in 18 clinical centres in France.
Duration of follow-up: 24 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial performed randomization of participants by
using computer-generated random numbers
Allocation concealment (selection bias) Low risk The trial performed allocation centrally.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial authors used ITT for the primary outcome.
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Katlama 2002 (Continued)
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk We did not identify any other potential sources of bias.
Kelleher 1998
Methods This was a single centred pilot study which was planned as a pilot study of a multi-
centred RCT to be conducted
Participants 18 participants consecutively enrolled into 3 groups
Inclusion criteria
• Adults who had asymptomatic HIV infections.
• CD4 counts between 200 to 500 cells/mm³.
• Receiving nucleoside analogue ART regimen.
Exclusion criteria: not specified
Interventions Treatment group A (IL-2 plus ART only)
• IL-2 at doses of 12.6 X 106 U/day
as continuous intravenous infusions for 5 days every 8 weeks for 6 cycles
Treatment group B (IL-2 linked to polyethylene glycol plus ART)
• Escalating doses of subcutaneous injections of IL- 2 on day 1 and 3 of each 8-
week cycle.
Control group
• ART alone.
Each group had 150 mg of lamivudine twice daily added to their regimen at 30 weeks
Outcomes • CD4 cell counts.
• Viral loads.
• Responses to recall antigens.
Notes This was a multicentred trial conducted in Australia.
Duration of follow-up: 48 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of random sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the
outcomes measures are objective and un-
likely to have been influenced by lack of
blinding
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Kelleher 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the
outcomes measures are objective and un-
likely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial excluded less than 15% of the par-
ticipants.
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing.
Other bias Low risk We did not identify any other potential
sources of bias.
Kovacs 1996
Methods This was a single-centred RCT
Participants A total of 60 participants were randomized
Inclusion criteria
• HIV-postive participants aged 18 years and older.
• No history of opportunistic infection.
• CD4 counts > 200 cells/mm³.
• Not received corticosteroids or cytotoxic chemotherapy.
• participants who had not received any experiment al therapy in the preceding 4
weeks.
Exclusion criteria: not specified
Interventions Treatment group: intravenous IL-2 given at intermittent infusions of 18 miu plus ART
Control group: ART alone consisting of zidovudine, zalcitabine, or stavudine with di-
danosine
Outcomes • Viral load.
• CD4 cell count.
Notes Study was conducted in the USA.
The duration of follow-up was 14 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the method of se-
quence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the method of allo-
cation concealment
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Kovacs 1996 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes
measures are objective and unlikely to have been in-
fluenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes
measures are objective and unlikely to have been in-
fluenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 15% were lost to follow-up and the trial
authors described withdrawals
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk We did not identify any other potential sources of bias.
Lalezari 2000
Methods Multicentred phase 2 RCT
Participants A total of 115 participants
Inclusion criteria
• HIV-infected individuals on ART ( highly active antiretroviral therapy)
• CD4 cell count < 300 cells/mm³.
• Viral load < 500 copies/mL.
• ART experienced.
Exclusion criteria: not specified
Interventions Treatment group (IL-2 plus ART): 51 participants
• Low dose IL-2 administered subcutaneously at 1.2 miu once daily for 6 months
Control group: ART alone
• participants continued on their current regimen and received HAART alone
Outcomes • CD4 cell counts.
• Adverse effects.
• Viral load.
Notes This trial was conducted in the USA.
Duration of follow-up: 26 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generation was by block randomization strati-
fied by study site
Allocation concealment (selection bias) Low risk The trial authors used a central randomization process.
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Lalezari 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcomes mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk More than 15% withdrew from the trial due to adverse
effects and the trial authors did not analyse their results
Selective reporting (reporting bias) Low risk There was no evidence of selective outcome reporting.
Other bias Low risk There was no evidence of any other sources of bias.
Levy 1999
Methods Multicentred an open label RCT
Participants A total of 94 participants
Inclusion criteria
• Participants aged 18 years and above.
• With asymptomatic HIV infection.
• ART naive.
• Also naive to corticosteroids, chemotherapy, and experimental therapy.
• CD4 counts between 250 to 550 cells/mm³.
Exclusion criteria: not specified
Interventions • Polyethylene-glycol (PEG) modified IL-2 administered as 2 miu intravenous
bolus for 7 cycles from 2nd week to 50th week plus ART
• Control group: ART alone.
Outcomes • Proportion of people with 80% rise in CD4 count.
• Change in CD4 cell count.
• Viral load change from baseline to end of study.
• Adverse effects.
Notes This study was conducted in 14 university clinics in France.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the method of
random sequence generation
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Levy 1999 (Continued)
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the method of
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcome
measures are objective and unlikely to have been
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcome
measures are objective and unlikely to have been
influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no evidence of incomplete outcome data.
Less than 15% were lost to follow-up
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting bias.
Other bias Low risk There was no evidence of other sources of bias.
Levy 2003
Methods This was a prospective RCT.
Participants There were a total of 118 participants
Inclusion criteria
• Asymptomatic HIV participants who were either completely ART naive or naive
to PIs alone.
• Were over 18 years of age.
• Had a CD4 cell count of between 200 to 550 cells/mm³.
Exclusion criteria: not specified
Interventions Treatment group: ART started 4 weeks before plus subcutaneous IL-2 administered at
a dose of 5 miu twice daily for 5 days given every 4 weeks for the first 3 cycles and then
subsequently every 8 weeks for the next 7 cycles
Control group: ART alone consisting of lamivudine (300 mg/day), stavudine (60 to
80mg/day), and indinavir (2400 mg/day)
Outcomes • Absolute and percentage change in CD4 cell counts.
• Proportion of participants with at least a 50% rise in CD4 cell counts at weeks 72
to 74 from baseline.
• Viral load.
• AIDS defining events.
• Adverse effects.
• Adherence.
Notes This was a multicentred study conducted in 14 university clinics in France
Duration of follow-up was 18 months.
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Levy 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors did not describe the method of se-
quence generation. However, the trial authors men-
tioned that randomization was centralized and stratified
according to ART status
Allocation concealment (selection bias) Low risk The trial authors used a centralized method of random-
ization
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcome mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcome mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial excluded less than 15% (2 out of 118 partic-
ipants) from the analysis. There was no differential loss
to follow-up
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk There was no evidence of other sources of bias.
Losso 2000
Methods Study design was a prospective open-labelled RCT
Participants There were a total of 73 participants
Inclusion criteria
• HIV participants who had been on ART For greater than or equal to 7 days.
• Not pregnant with a Karnofsky performance score ≥ 80.
• Were over 18 years of age.
• Had a most recent CD4 cel count of > 350 cells/mm³.
Exclusion criteria
• History of or presence of AIDS defining illness.
• History of malignancy requiring systemic use of corticosteroids or immuno
modulators within the prior 5 years.
• Autoimmune/inflammatory disease like Crohns disease.
Interventions • Treatment group: subcutaneous IL-2 given at escalating doses of 1.5 miu, 4.5 miu,
7.5 miu with ART given twice daily for 5 consecutive days every 8 weeks plus ART.
• Control group: ART alone.
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Losso 2000 (Continued)
Outcomes • Proportion of participants with viral load ≤ 500 copies/mL.
• Mean change in CD4 cell count.
• Mean change in viral load.
Notes This was a multi-centred trial conducted in 6 clinical centres in Buenos Aires, Argentina
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial used a stratified block randomiza-
tion method, using blocks of 24 stratified
according to ART history (naive or experi-
enced) and clinical centres
Allocation concealment (selection bias) Low risk The trial used a centralized method of ran-
domization.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the
outcome measures are objective and un-
likely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the
outcome measures are objective and un-
likely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial excluded less than 15% (2 out of
73 participants) from the analysis. There
was no differential loss to follow-up
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing.
Other bias High risk There was more monitoring in the treat-
ment group compared to the control group
Marchetti 2002
Methods Open labelled parallel RCT
Participants 22 participants were randomized:
Inclusion criteria
• 18 years and above.
• Immunological non-responders (INRs), that is participants on ART showing
failure to restore their circulating CD4 counts despite good control of HIV plasma
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Marchetti 2002 (Continued)
viraemia and have received an ART regimen consisting of 2 nucleoside reverse
transcriptase inhibitors (NRTI) and 1 PI for at least a year.
• Have HIV RNA load of < 50 copies/mL for at least 6 months.
Exclusion criteria
• Pregnant women.
• Active drug users (alcohol abusers).
• participants with cardiovascular and thyroid disorders.
• Previously treated with cytotoxic drugs or growth factors.
• participants who were previously not compliant with ART medication.
Interventions Treatment group (12): they were commenced on IL-2 for a 4 week cycle for 3 cycles plus
ART
Control group (10): ART consisting of 2 nucleoside reverse transcriptase inhibitors
(NRTI) and 1 PI
Outcomes • Proportion of participants with undetectable viral load.
• Mean change in CD4 count.
• Change in CD8 count.
• Opportunistic infections.
• Adverse events.
Notes This trial was an explanatory trial conducted at the University of Milan, Italy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe themethod of sequence
generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the method of alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcome mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcome mea-
sures are objective and unlikely to have been influenced
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial followed up all participants to the end of the
trial, and even included those who were lost to follow-up
afterwards in the results
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting bias.
Other bias Low risk There was no evidence of other potential sources bias.
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Marchetti 2004
Methods This was a RCT
Participants There were a total of 15 participants
Inclusion criteria
• Participants on ART showing failure to restore their circulating CD4 counts
despite good control of HIV plasma viraemia and have received ART regimen
consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 PI for at least a
year.
• CD4 cell counts constantly less than or equal to 200 cells/mm³ and HIV RNA
load of < 50 copies/mL after 12 months of stable ART.
Exclusion criteria
• Not specified.
Interventions Treatment group (8): participants received 3 cycles of low dose subcutaneous IL-2 over
a 48-week period. Each cycle consisted of 3 miu IL-2 administered at days of 1 to 5 and
days 8 to 12 of a 10-week duration plus ART
Control group (7): ART alone
Outcomes • Percentage change in CD4 count.
• Absolute change in CD4 count.
Notes This was a small immunological trial conducted to investigate the long-term kinetics of
CD4 and CD8 cells when low dose IL-2 is administered in Milan, Italy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the method of sequence gen-
eration
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the method of allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcome measures are
objective and unlikely to have been influenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcome measures are
objective and unlikely to have been influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no loss to follow-up.
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting of outcomes.
Other bias Low risk We did not identify any other potential sources of bias.
41Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Mitsuyasu 2007
Methods This was a multi-arm parallel RCT
Participants There were a total of 159 participants
Inclusion criteria
• HIV-positive participants without AIDS defining illness.
• ART naive or had been treated only reverse transcriptase inhibitors (RTI) and 1
PI for at least a year.
• CD4 cell counts constantly from 50 to 350 cells/mm³ and HIV RNA load of <
50 copies/mL after 12 months of stable ART.
Exclusion criteria
• Previous use of PIs or IL-2 therapy.
• Cardiac disease.
Interventions Treatment group A (intravenous IL-2 plus ART): received continuous infusions of IL-2
at doses of 9 miu for 5 days every 8 weeks plus ART
Treatment group B (subcutaneous IL-2 plus ART): received subcutaneous injections of
IL-2 7.5 miu twice daily for 5 days every 8 weeks plus ART
Control group: ART alone, 2 NRTIs, and a PI
Outcomes • Change in CD4 countChange in plasma viral levels.
• Adverse effects.
• All-cause mortality.
Notes This was a multicentred trial conducted at 26 AIDS Clinical Trials Group (ACTG) sites
in the USA
Duration of the trial was 84 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk There is likely to be a low risk of selection bias
because although the trial authors did not de-
scribe the method of sequence generation, partic-
ipants were randomized in proportions of 1:1:1
and stratified by participation in a previous trial
ACTG 928 and nucleosides
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the method of
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcome
measures are objective and unlikely to have been
influenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcome
measures are objective and unlikely to have been
influenced by lack of blinding
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Mitsuyasu 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk The trial excluded more than 15% of participants
from the analysis
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk There was no evidence of other potential sources
of bias.
Ruxrungtham 2000
Methods Multicentred parallel RCT
Participants Inclusion criteria
• HIV-infected adults.
Exclusion criteria
• History of AIDS defining illness, malignancy needing treatment within the last 5
years, medical condition corticosteroids, or cytotoxic chemotherapy.
Interventions Treatment groups (A, B, and C): received 1.5 miu, 4.5 miu, and 7.5 miu of IL-2 admin-
istered twice daily for 5 days, every 8 weeks for three cycles
Control groups: ART alone.
Outcomes • Change in CD4 count.
• Change in viral load.
• Proportion of undetectable viral load.
Notes This was a multi-arm pragmatic trial conducted in Thailand.
Duration of follow-up was 24 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial authors did not clearly specify the method of
random sequence generation but it appeared to be low risk.
Randomization was stratified by clinical centre and ART
treatment history, that is naive or pretreated
Allocation concealment (selection bias) Unclear risk The trial authors did not describe themethod of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded.However, the outcomemeasures
are objective and unlikely to have been influenced by lack
of blinding
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Ruxrungtham 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded.However, the outcomemeasures
are objective and unlikely to have been influenced by lack
of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial authors did not describe withdrawals or missing
data
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk There was no evidence of other potential sources of bias.
Stellbrink 2002
Methods Prospective RCT
Participants There were 56 participants.
Inclusion criteria
• Asymptomatic HIV participants.
• Had a CD4 cel count of > 350 cells/mm³.
• plasma viral load> 400 copies/mL.
• Had seroconverted 12 months prior to entry.
• Aged between 18 to 70 years.
Exclusion criteria
• History of AIDS defining illness (Castro 1992).
• Malignancy needing treatment within the last 5 years.
• Medical condition corticosteroids.
Interventions • Treatment group (27): ART plus recombinant subcutaneous IL-2 at 9 MU
(megaunits) once daily (with an option to switch to 4.5 MU twice daily) for 5
consecutive day
• Control group (29): ART alone consisting of stavudine 30 to 40 mg twice daily,
and lamivudine 150 mg twice daily, nelfinavir 750 mg 3 times daily, and saquinavir
600 mg 3 times daily.
Outcomes • Change in CD4 count
• Change in plasma viral levels
Notes This was an open label RCT conducted in Germany. Mean follow-up duration ranged
from 582 - 601 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not report the method of sequence gener-
ation
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Stellbrink 2002 (Continued)
Allocation concealment (selection bias) Unclear risk The trial authors did not report the method of allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcome measures are
objective and unlikely to have been influenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcome measures are
objective and unlikely to have been influenced by lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial authors performed analysis was ITT and there were no
losses to follow-up
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias Low risk There was no evidence of other potential sources of bias.
Tambussi 2001
Methods This was a phase 2 RCT.
Participants There was a total of 61 participants.
Inclusion criteria
• HIV-infected adults with CD4 cell count of between 200 to 550 cells/mm³,
plasma viral load > 400 copies/mL.
Exclusion criteria: not specified
Interventions Treatment arm A (high dose intravenous arm): ART plus 12 miu of IL-2 by continuous
intravenous infusion followed by subcutaneous 7.5 miu IL-2 twice a day for 5 days every
8 weeks for the remaining 4 cycles
Treatment arm B (high dose subcutaneous arm): ART+subcutaneous 7.5 miu IL-2 twice
a day for 5 days every 8 weeks for 6 cycles
Treatment arm C (low dose arm): ART plus subcutaneous IL-2 +3 miu twice a day every
4 weeks
Control: ART alone
Outcomes • Change in CD4 count.
• Change in plasma viral levels.
• Adverse effects.
Notes This was an phase 2 RCT conducted in Milan Italy. The duration of follow-up was a 12
months
Risk of bias
Bias Authors’ judgement Support for judgement
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Tambussi 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk The trial authors did not report the method of sequence
generation
Allocation concealment (selection bias) Unclear risk The trial authors did not report the method of allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the outcome measures
are objective and unlikely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the outcome measures
are objective and unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial authors performed analysis by ITT principle and
less than 15% of participants were lost to follow-up
Selective reporting (reporting bias) Low risk There was no evidence of selective reporting.
Other bias High risk There were differential treatment participants in the 2
groups. Participants were followed up as outpatients in 1
group and as inpatients in the other group
Tavel 2003
Methods This was a double blinded randomized placebo controlled trial
Participants There were a total of 19 participants.
Inclusion criteria
• HIV-positive participants with a CD4 cell count ≥ 350 cells/mm³ ≤ 1 month
before the trial.
• Had been stable on 2 nucleosides analogue reverse transcriptase inhibitor and
either a non-nucleoside analogue reverse transcriptase inhibitor or PI.
Exclusion criteria
• History of AIDS defining illness.
• Malignancy requiring treatment during the preceding 5 years.
• Medical conditions requiring cytotoxic chemotherapy.
Interventions Group A: subcutaneous IL-2 (7.5 miu IL-2 twice daily for 5 days) and placebo) plus
ART
Group B: IL-2 (7.5 miu IL-2 twice daily for 5 days) and 0.5 mg prednisone/kg/day for
7 days every 8 weeks plus ART
Group C: 0.5 mg prednisone/ kg/day for 7 days every 8 weeks plus ART
Group D: placebo orally for 7 days (1 cycle ) every 8 weeks plus ART
Outcomes • Viral load
• Change in CD4 cell count.
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Tavel 2003 (Continued)
Notes This study was conducted in the USA. Duration of follow-up was 12 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the
outcome measures are objective and un-
likely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the
outcome measures are objective and un-
likely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There was no loss to follow-up and ITT.
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing.
Other bias Low risk There was no evidence of other potential
sources of bias.
Vogler 2004
Methods This was a phase 2 multi-centred randomized open label trial
Participants There was a total of 115 participants
Inclusion criteria
• HIV-infected participants confirmed by serology, > 18 years old.
• CD4 cell count of between 300 to 700 cells/mm³.
• Stable on single or dual nucleoside therapy for at least 2 months.
• No history of AIDS defining illness (Castro 1992)
• No IL-2 treatment within the last 3 months.
Exclusion criteria
• History of AIDS defining illness.
• Systemic malignancies, or cardiac disease, or untreated thyroid disease.
• Pregnant and breast feeding women, as well as asthmatic and autoimmune disease
participants.
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Vogler 2004 (Continued)
• Active opportunistic infection.
• No immunomodulating drugs, or cytotoxic chemotherapy, or systemic
corticosteroids at least 4 weeks before trial.
Interventions Treatment group: self administered subcutaneous IL-2 1 miu daily in 0.2 mL volume at
rotating skin sites in combination with continued ART
Control: ART alone.
Outcomes • Viral load.
• Change in CD4 cell count.
• Adverse effects.
• Adherence.
• All-cause mortality.
Notes This trial was conducted in the USA.
The duration of follow-up was 24 weeks.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial authors did not describe the
method of sequence generation
Allocation concealment (selection bias) Unclear risk The trial authors did not describe the
method of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was not blinded. However, the
outcome measures are objective and un-
likely to have been influenced by lack of
blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial was not blinded. However, the
outcome measures are objective and un-
likely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The trial excluded less than 15% from the
analysis.
Selective reporting (reporting bias) Low risk There was no evidence of selective report-
ing.
Other bias Low risk There was no evidence of other potential
sources of bias.
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Abbreviations: AIDS: acquired immunodeficiency virus; ART: antiretroviral therapy; CNS: central nervous system; PEG: polyethylene
glycol; HIV: human immunodeficiency virus; ITT: intention to treat; IL-2: interleukin-2; NRTI: nucleoside reverse transcriptase
inhibitors; PI: protease inhibitor; RCT: randomized controlled trial; USA: United States of America.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bosch 2010 Both the intervention and control group received interleukin-2 (IL-2)
Chun 1999 This was a cross-sectional study
Crespo 2008 This was a cohort study
Jacobson 2002 This was a study of interleukin-12 (IL-12) and not IL-2
Kilby 2006 Participants in the intervention group received both IL-2 and a vaccine
Lafeuillade 2001 Participants in the intervention group received both IL-2 and interferon-gamma
Martin 2005 The study did not report any outcomes relevant to this review
Pett 2001 This was a review of randomized controlled trials
Tavel 2010 The study compared participants receiving no treatment, IL-2 alone, or IL-2 with antiretroviral treatment (ART)
Witzke 1998 Here the comparison was between subcutaneous IL-2 and ART and intravenous IL-2 and ART. The control group
was not relevant to this review
Abbreviations: IL-2: interleukin-2.
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D A T A A N D A N A L Y S E S
Comparison 1. Interleukin-2 versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 6 6565 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.80, 1.17]
1.1 ART experienced 2 626 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.16, 7.11]
1.2 ART naive or not specified 4 5939 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.80, 1.17]
2 HIV RNA levels < 50 cells/mL 5 805 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
3 HIV RNA levels < 500 cells/mL 4 5929 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.82, 1.12]
4 Opportunistic infections 7 6141 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.55, 1.13]
4.1 ART experienced 2 97 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.05, 1.86]
4.2 ART naive or not specified 5 6044 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.56, 1.19]
5 Adverse events (grade 3 or 4) 6 6291 Risk Ratio (M-H, Random, 95% CI) 1.47 [1.10, 1.96]
Analysis 1.1. Comparison 1 Interleukin-2 versus control, Outcome 1 All-cause mortality.
Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
Comparison: 1 Interleukin-2 versus control
Outcome: 1 All-cause mortality
Study or subgroup IL-2 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ART experienced
Abrams 2002 2/256 1/255 0.6 % 1.99 [ 0.18, 21.83 ]
Vogler 2004 0/57 1/58 0.4 % 0.34 [ 0.01, 8.15 ]
Subtotal (95% CI) 313 313 1.0 % 1.05 [ 0.16, 7.11 ]
Total events: 2 (IL-2), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
2 ART naive or not specified
Abrams 2009a 107/2071 116/2040 56.5 % 0.91 [ 0.70, 1.17 ]
Abrams 2009b 81/849 77/846 41.8 % 1.05 [ 0.78, 1.41 ]
Kovacs 1996 1/31 0/29 0.4 % 2.81 [ 0.12, 66.40 ]
Losso 2000 0/36 1/37 0.4 % 0.34 [ 0.01, 8.14 ]
0.01 0.1 1 10 100
Favours IL-2 Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup IL-2 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 2987 2952 99.0 % 0.97 [ 0.80, 1.17 ]
Total events: 189 (IL-2), 194 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 3300 3265 100.0 % 0.97 [ 0.80, 1.17 ]
Total events: 191 (IL-2), 196 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.13, df = 5 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.01 0.1 1 10 100
Favours IL-2 Favours control
Analysis 1.2. Comparison 1 Interleukin-2 versus control, Outcome 2 HIV RNA levels < 50 cells/mL.
Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
Comparison: 1 Interleukin-2 versus control
Outcome: 2 HIV RNA levels < 50 cells/mL
Study or subgroup IL-2 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abrams 2002 165/256 158/255 31.4 % 1.04 [ 0.91, 1.19 ]
Davey 2000 20/39 13/43 8.0 % 1.70 [ 0.98, 2.93 ]
Levy 1999 37/58 47/60 22.6 % 0.81 [ 0.64, 1.03 ]
Marchetti 2002 9/12 10/10 14.8 % 0.77 [ 0.54, 1.09 ]
Ruxrungtham 2000 29/36 29/36 23.2 % 1.00 [ 0.80, 1.25 ]
Total (95% CI) 401 404 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 260 (IL-2), 257 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.32, df = 4 (P = 0.05); I2 =57%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IL-2 Favours control
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Analysis 1.3. Comparison 1 Interleukin-2 versus control, Outcome 3 HIV RNA levels < 500 cells/mL.
Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
Comparison: 1 Interleukin-2 versus control
Outcome: 3 HIV RNA levels < 500 cells/mL
Study or subgroup IL-2 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abrams 2009a 104/2071 107/2040 35.7 % 0.96 [ 0.74, 1.25 ]
Abrams 2009b 83/849 92/846 31.2 % 0.90 [ 0.68, 1.19 ]
Levy 1999 14/24 16/26 11.9 % 0.95 [ 0.60, 1.49 ]
Losso 2000 24/36 23/37 21.2 % 1.07 [ 0.76, 1.51 ]
Total (95% CI) 2980 2949 100.0 % 0.96 [ 0.82, 1.12 ]
Total events: 225 (IL-2), 238 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IL-2 Favours control
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Analysis 1.4. Comparison 1 Interleukin-2 versus control, Outcome 4 Opportunistic infections.
Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
Comparison: 1 Interleukin-2 versus control
Outcome: 4 Opportunistic infections
Study or subgroup IL-2 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 ART experienced
Carr 1998 1/27 2/30 2.3 % 0.56 [ 0.05, 5.79 ]
Hengge 1998 0/22 3/18 1.5 % 0.12 [ 0.01, 2.15 ]
Subtotal (95% CI) 49 48 3.8 % 0.30 [ 0.05, 1.86 ]
Total events: 1 (IL-2), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
2 ART naive or not specified
Abrams 2009a 68/2071 63/2040 45.4 % 1.06 [ 0.76, 1.49 ]
Abrams 2009b 49/849 66/846 43.3 % 0.74 [ 0.52, 1.06 ]
Katlama 2002 1/36 2/36 2.3 % 0.50 [ 0.05, 5.27 ]
Kovacs 1996 1/31 2/29 2.3 % 0.47 [ 0.04, 4.89 ]
Mitsuyasu 2007 1/54 7/52 3.0 % 0.14 [ 0.02, 1.08 ]
Subtotal (95% CI) 3041 3003 96.2 % 0.81 [ 0.56, 1.19 ]
Total events: 120 (IL-2), 140 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 5.72, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI) 3090 3051 100.0 % 0.79 [ 0.55, 1.13 ]
Total events: 121 (IL-2), 145 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.67, df = 6 (P = 0.26); I2 =22%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 1.10, df = 1 (P = 0.30), I2 =9%
0.01 0.1 1 10 100
Favours IL-2 Favours control
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Analysis 1.5. Comparison 1 Interleukin-2 versus control, Outcome 5 Adverse events (grade 3 or 4).
Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults
Comparison: 1 Interleukin-2 versus control
Outcome: 5 Adverse events (grade 3 or 4)
Study or subgroup IL-2 Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abrams 2009a 203/2071 186/2040 28.7 % 1.08 [ 0.89, 1.30 ]
Abrams 2009b 466/849 383/846 31.6 % 1.21 [ 1.10, 1.33 ]
Davey 2000 20/39 7/43 10.2 % 3.15 [ 1.50, 6.63 ]
Lalezari 2000 11/56 12/59 10.5 % 0.97 [ 0.46, 2.01 ]
Levy 1999 21/153 2/26 3.8 % 1.78 [ 0.44, 7.16 ]
Levy 2003 34/53 12/56 15.2 % 2.99 [ 1.74, 5.14 ]
Total (95% CI) 3221 3070 100.0 % 1.47 [ 1.10, 1.96 ]
Total events: 755 (IL-2), 602 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 19.26, df = 5 (P = 0.002); I2 =74%
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IL-2 Favours control
A D D I T I O N A L T A B L E S
Table 1. Details of the interleukin-2 intervention regimen
Number Trial ID Follow-up dura-
tion
Dosing regimen
for interleukin-2
(IL-2)
Comparisons Outcomes ART experienced
or naive
1 Abrams 2002 16 months Dose: 2 doses (4.5
and 7.5 miu)
Route:
subcutaneous
Du-
ration: twice daily
for 5 days every 8
weeks
ART not specified Viral load
CD4 cell count
ART experienced
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Table 1. Details of the interleukin-2 intervention regimen (Continued)
2 Abrams 2009b 7 years Dose: 4.5 miu
Route:
subcutaneous
Duration: twice
daily, 6 cycles
ART not specified Opportunistic in-
fections
Death from any
cause
Adverse events
Not specified
3 Abrams 2009a 7 years Dose: 7.5 miu
Route:
subcutaneous
Duration: twice
daily, 3 cycles
ART not specified Opportunistic in-
fections
Death from any
cause
Adverse events
Not specified
4 Amendola 2000 28 weeks Dose: 1 miu
Route:
subcutaneous
Duration:
daily for 5 days/
week every alter-
nate week for 3
months
Indinavir, stavu-
dine, and lamivu-
dine
CD4 cell count
Viral load
ART naive
5 de Boer 2003 12 months Dose: 12 miu
Route:
intravenous
Duration: for 3, 4,
or 5 days every 8
weeks for 6 cycles
ART not specified CD4 cell count
Viral load
Adverse
events and serious
adverse events
AIDS defining
complex
ART experienced
6 Caggiari 2001 12 months Dose: 6 miu
Route:
subcutaneous
Dura-
tion: from days 1
to 5 and days 8 to
12 of a 28-day cy-
cle for 6 cycles
2 nucleoside re-
verse transcriptase
inhibitors
(NRTIs) or 2NR-
TIs and indinavir
CD4 cell count
Viral load
ART naive
7 Carr 1998 12 months Dose: 1 miu
Route:
subcutaneous and
intravenous
Duration: Group
A: 12 miu daily
for 5 days every 8
weeks (27 partici-
pants)
Group B: 1 miu
Zidovudine + di-
danosine + zal-
citabine
CD4 cell count
Adverse events
Viral load
Opportunistic in-
fections
ART experienced
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Table 1. Details of the interleukin-2 intervention regimen (Continued)
per cycle in equal
divided doses in
day 1 and 3 every
8 weeks (58 par-
ticipants)
8 Davey 2000 48 weeks Dose: 7.5 miu
Route:
subcutaneous
Duration: 6 cycles
every 12 hours for
5 days every 8
weeks
ART not specified CD4 cell count
Viral load
Adverse events
ART experienced
9 Dybul 2002 12 months Dose: 7.5 miu
Route:
subcutaneous
Duration: 3 cycles
for 5 days every 8
week
ART not specified CD4 cell count
Viral load
Not specified
10 Hengge 1998 12 months Dose: 9.6 miu
Route:
subcutaneous
Duration: 5 cycles
were given. One
cycle was given ev-
ery 6 weeks over a
period of 52weeks
Treatment
group A : subcu-
taneous adminis-
tered daily in cy-
cles consisting of 5
days
Treatment group
B: subcutaneous
administered at a
dose of 9.
6 miu daily when-
ever CD4 counts
dropped to below
1.25 fold of in-
dividual’s baseline
value
Saquinavir,
lamivudine, and
zidovudine
CD4 cell count
Viral load
Opportunistic in-
fections
ART experienced
11 Katlama 2002 24
weeks with out-
comes measured
at weeks 1, 6, 12,
Dose: 4.5 miu
Route:
subcutaneous
Duration: every 6
2 nucleoside ana-
logues and one PI
CD4 cell count
Viral load
Adverse events
Not specified
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Table 1. Details of the interleukin-2 intervention regimen (Continued)
18, and 24 weeks for 4 cycles,
every 12 hours for
5 days
ART experienced
12 Kelleher 1998 48 weeks Dose: 12 miu
Route:
intravenous
Duration: Group
A: 12.6 miu as
continuous intra-
venous infusions
for 5 days ev-
ery 8 weeks for
6 cycles. Group
B (IL-2 linked to
polyethylene gly-
col plus ART):
subcutaneous in-
jections on days 1
and 3 of each 8-
week cycles
ART included nu-
cleoside analogues
such as lamivu-
dine
CD4 cell count
Viral load
ART experienced
13 Kovacs 1996 14 months Dose: 18 miu
Route:
intravenous
Duration:
daily for 5 days ev-
ery other month
for 6 cycles from
month 0 to 10
ART included di-
danosine, zidovu-
dine, zalcitabine,
or stavudine
CD4 cell count
PlasmaHIV RNA
Not specified
14 Lalezari 2000 6 months Dose:
1.2 miu, and then
increased by 0.3
miu every 2 weeks
for 6months until
a participant expe-
rienced grade 2 or
greater toxicity
Route:
subcutaneous
Duration: once
daily for 2 weeks
ART not specified CD4 cell count
Viral load
Adverse events
ART experienced
15 Levy 1999 14 months Dose: 12 miu and
3 miu
Route: 12 miu in-
travenous and 3
miu subcutaneous
Zidovudine (600
mg/
day) plus didano-
sine (400 mg/day)
CD4 cell count
Viral load
Adverse events
ART naive
57Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Details of the interleukin-2 intervention regimen (Continued)
intravenously (12
miu/day, N = 22)
or subcutaneously
(3 miu/m² twice
daily, N = 24)
for 5 days, or
2 miu/m² intra-
venous bolus, N =
22) administered
every 2 months
from week 2 to
week 50 (7 cycles)
16 Levy 2003 18 months Dose: 5 miu
Route:
subcutaneous
Duration:
twice daily for a 5
day cycle given ev-
ery 4 weeks for the
first 3 cycles and
then subsequently
every 8 weeks for
the next 7 cycles
ART included
lamivudine (300
mg/day), stavu-
dine (60 to 80mg/
day) and indinavir
(2400 mg/day)
CD4 cell counts
Viral load
AIDS defining
events
ART naive or
naive to PIs alone
17 Losso 2000 24 weeks Dose:
escalating doses of
1.5 miu, 4.5 miu,
7.5 miu
Route:
subcutaneous
Duration: twice
daily for 5 consec-
utive days every 8
weeks
ART not specified CD4 cell counts .
Viral load
Both naive and ex-
peri-
enced participants
were included in
the study
18 Marchetti 2002 48 weeks Dose: 3 miu
Route:
subcutaneous
Duration: admin-
istered as a single
subcutaneous in-
jection at days 1 to
5 and 8 to 12 of a
4-week cycle, for a
total of 3 cycles
ART was either
2 nucleoside re-
verse transcriptase
inhibitor
and one
PI or at least one
non nucleoside re-
verse transcriptase
inhibitor
CD4 cell count
Viral load
Adverse events
ART experienced
19 Marchetti 2004 48 weeks Dose: 3 miu
Route:
ART not specified CD4 cell count ART experienced
58Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Details of the interleukin-2 intervention regimen (Continued)
subcutaneous
Duration: admin-
istered at day 1 to
5 and 8 to 12 for
10 weeks
20 Mitsuyasu 2007 84 weeks Dose: Group A 9
miu and Group B
7.5miu
Route: intra-
venous and sub-
cutaneous
Duration: Group
A: intravenous in-
fusions 5 days ev-
ery 8 weeks
Group B: subcu-
taneous injections
7.
5 miu twice daily
for 5 days every 8
weeks
Received
ART alone, 2 nu-
cleosides and a PI
CD4 cell count
Viral load
Not specified
21 Ruxrungtham
2000
24 weeks Dose: Group A 1.
5miu, Group B 4.
5 miu, and Group
C 7.5 miu
Route:
subcutaneous
Du-
ration: twice daily
for 5 days, every 8
weeks for three cy-
cles 8-weekly
ART not specified CD4 cell count
Viral load
ART experienced
22 Stellbrink 2002 601 days Dose: 9 miu
Route:
subcutaneous
Duration: once
daily (with an op-
tion to switch to 4.
5 miu twice daily)
for 5 consecutive
days per cycle ad-
ministered at 6-
weekly intervals
ART consisting of
stavudine
30 to 40 mg twice
daily, and lamivu-
dine 150 mg twice
daily,
nelfinavir 750 mg
3 times daily and
saquinavir 600
mg 3 times daily
CD4 cell count
Viral load
ART naive
23 Tambussi 2001 12 months Dose: 3 regimens
of IL-2
2 NRTIs and
saquinavir
CD4 cell count
Viral load
ART experienced
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Table 1. Details of the interleukin-2 intervention regimen (Continued)
Route: intra-
venous and sub-
cutaneous
Duration:dif-
fered by group see
details below
Group A: 12 miu
by continuous in-
travenous in-
fusion followed by
subcutaneous 7.5
miu twice a day
for 5 days every 8
weeks for the re-
maining 4 cycles
Group B: subcu-
taneous 7.5 miu
twice a day for 5
days every 8 weeks
for 6 cycles
Group C: sub-
cutaneous 3 miu
twice a day every 4
weeks
24 Tavel 2003 12 months Dose: 7.5 miu
Route:
subcutaneous
Dura-
tion: Group A: 7.
5 miu twice daily
for 5 days versus
placebo plus ART
Group B: 7.5 miu
twice a day for 5
days
Nucleosides ana-
logue reverse tran-
scriptase inhibitor
and either a non-
nucleosides ana-
logue reverse tran-
scriptase inhibitor
or PI
CD4 cell count
Viral load
ART experienced
25 Vogler 2004 24 weeks Dose: 1 miu
Route:
subcutaneous
Duration: once
daily
2 nucleoside re-
verse transcriptase
inhibitors
CD4 cell count
Viral load
ART experienced
Abbreviations: ART antiretroviral therapy; IL-2 Interleukin 2; NRTI nucleoside reverse transcriptase inhibitors; PI protease inhibitor
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Table 2. Effect of intervention: change in CD4 count
Increase in CD4 cell count with statistically significant difference
Abrams 2002
(at 12 months follow-up)
n = 511
The average difference change in CD4 cell count between the IL-
2 group and control group was 217.1 cells/mm³ (95% CI 188.6
to 245.5; P < 0.001) measured at 12 months
Carr 1998
(at 12 months follow-up)
n = 115
Median CD4 cell count increases of 359 and 44 cells/mm³ and
a decline of 46 cells/mm³ in the cyclical continuous intravenous
IL-2, subcutaneous IL-2, and ART alone group, respectively, over
12 months (P < 0.0001 for each intergroup comparison)
Davey 2000
(at 12 months follow-up)
n = 82
The median increase in CD4 count at 12 months was 279 cells/
mm³ in the IL-2 group comparedwith 50 cells/mm³ in the control
(P < 0.001)
de Boer 2003
n = 81
The mean per cent increase in CD4 cell counts was 24.5% for IL-
2 recipients compared to a mean per cent decrease of 30.5% for
control participants (P < 0.005)
Hengge 1998
(at 12 months follow-up)
n = 64
The median CD4 cell counts increased from 363 to 485 (+ 33.
6% standard deviation) in the IL-2 group Group A (P < 0.01) and
from 358 to 462 (+ 29.1%) in Group B (P < 0.01) and from 350
to 375 (+ 6.9% in the control group (not significant), respectively
Katlama 2002
(at 24 weeks, that is 6 months follow-up)
n = 72
The median increase in CD4 cells at week 24 was significantly
higher in the IL-2 group than in the control group (65 versus 18
cells/mm³; P < 0.0001)
Kovacs 1996
(at 12 months follow-up)
n = 60
There was an increase in the mean (± SE) CD4 count from 428 ±
25 cells/mm³ at baseline to 916 ± 128 in the IL-2 group, compared
to a decreased from 406 ± 29 cells/mm3 to 349 ± 41 cells/mm³
in the control group (P < 0.001).
Lalezari 2000
(at 26 weeks follow-up)
n = 115
The percentage increase in CD4 count from baseline of 3.59% in
the IL-2 group compared to 1.33% in the control group (P < 0.
001)
Levy 1999
(at 56 weeks follow-up)
n = 94
The median increase in CD4 count from baseline at 56 weeks was
564 cells/mm³ (P > 0.0001), 105 cells/mm³ (P = 0.58), and 676
cells/mm³ (P = 0.0002) in the subcutaneous (SC), polyethylene
glycol modified, and intravenous (IV) IL-2 group respectively,
compared to 55 cells/mm³ in the control group
Levy 2003
(at 74 weeks follow-up)
n = 118
The median increase in CD4 count from baseline at week was
865 cells/mm³ in the IL-2 group compared to 262 cells/mm³ in
the control group (P < 0.00001)
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Table 2. Effect of intervention: change in CD4 count (Continued)
Losso 2000
(at 24 weeks follow-up)
n = 73
The mean increase in CD4 count from baseline at week 24 of 27
cells/mm³ (P = 0.105), 105 cells/mm³ (P = 0.006), and 492 cells/
mm³ (P < 0.001) in the 1.5, 4.5, and 7.5 miu dose groups of IL-
2. Overall 14 out of 36 (41%) of the IL-2 group and 3 out of 37
(8%) of the controls had a magnitude increase of ≥ 1000 cells/
mm³
Marchetti 2002
(48 weeks follow-up)
n = 22
IL-2 treated participants had mean absolute CD4 T cell counts
(S.E) significantly increase at the end of the IL-2 treatment (week
48) from 147 (18) cells/mm³ at baseline to 298 (43.3) cells/mm³
(P=0001). The control participants also had a significant increase
was observed 16 weeks 228 (29) cells/mm³ (P = 0.002)
Mitsuyasu 2007
(at 48 weeks follow-up)
n = 159
Reported median increases of CD4 cell count were 459, 312, and
102 cells/mm³ in the intravenous, SC Il-2, and control groups
respectively at 48 weeks (P < 0.001 for both)
Tavel 2003
(at 12 months follow-up)
n = 19
Reported a mean increase in CD4 count from baseline of 452
cells/mm3 in the IL-2 group compared to 135 cells/mm3 in the
control group (P < 0.05).
Ruxrungtham 2000
n = 82
Reported an increase in the time weighted mean CD4 cell count
252 x 106 cells/mm³ over 24 weeks for the overall scIL-2 group
compared with 42 x 106 cell/mm³.
Increase in CD4 cell count but statistical significance not reported in the trials
Abrams 2009a
(at 12 months follow-up)
(at 6 years follow-up)
n = 4111
Six trialsmeasured at 1 year;medianCD4 increase of 206 versus 21
cells/mm³ in the IL-2 group versus the control group and reported
an average median increase of 109 more in the IL-2 group more
than the control group over the entire 7 years (95% CI 40 to 60
over 6 years)
Abrams 2009b
(at 12 months follow-up)
n = 1695
Six trials measured at 1 year; median CD4 increase of 131 versus
32 cells/mm³ in the IL-2 group versus the control group over 12
months and reported an average median increase of 53 more in
the IL-2 group more than the control group over the entire 7 years
(95% CI 40 to 60 over 6 years)
Dybul 2002 (at 12 months follow-up)
n = 9
Four participants treated with HAART plus 3 cycles of intermit-
tent IL-2 had an increase in median absolute CD4+ T cell count
from 529 cells/mm³ (range: 502 to 738 cells/mm³) at enrolment
to 1995 cells/mm³ (range: 1112 to 3064 cells/mm³; 268% in-
crease) after 12months of treatment (Figure 1A). Five participants
treated with HAART alone had an increase in median CD4+ T
cell count from 580 cells/mm³ (range: 416 to 662 cells) at en-
rolment to 712 cells/mm³ (range: 667 to 1160 cells/mm³; 52%
increase) after 12 months of treatment
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Table 2. Effect of intervention: change in CD4 count (Continued)
No significant increase in CD4 cell count
Vogler 2004
(at 24 weeks)
n = 115
Mean change in CD4 count in the IL-2 group and the control
group was 40 and −1 respectively
Tambussi 2001
n = 61
Reports that there was a progressive increase in circulating CD4
cells, determined at the beginning of each IL-2 cycle, was observed
in all participants receiving ART plus IL-2, in comparison with
those receiving ART alone but gave the values for the within sub-
group variation
Amendola 2000
(at 6 months follow-up)
n = 22
No significant difference between changes in CD4 counts in both
groups
Abbreviations: ART: antiretroviral therapy; ESPIRIT: Evaluation of Subcutaneous Proleukin in a Randomised International Trial; IL-2:
interleukin-2; SILICAAT: subcutaneous recombinant human interleukin-2 in HIV-infected patients low CD4 counts under active
antiretroviral therapy
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Date: 26 May 2016
ID Search Hits
#1 MeSH descriptor: [HIV Infections] explode all trees 8930
#2 MeSH descriptor: [HIV] explode all trees 2820
#3 hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*)
or (human immunodeficiency virus) or (human immunede-
ficiency virus) or (human immune-deficiency virus) or (hu-
man immuno-deficiency virus) or (human immune deficiency
virus) or (human immuno deficiency virus) or (acquired im-
munodeficiency syndrome) or (acquired immunedeficiency
syndrome) or (acquired immuno-deficiency syndrome) or (ac-
quired immune-deficiency syndrome) or (acquired immun*
deficiency syndrome) (Word variations have been searched)
16171
63Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
#4 MeSH descriptor: [Lymphoma, AIDS-Related] this term only 23
#5 MeSH descriptor: [Sexually Transmitted Diseases, Viral] this
term only
25
#6 #1 or #2 or #3 or #4 or #5 16256
#7 MeSH descriptor: [Antiretroviral Therapy, Highly Active] this
term only
1161
#8 MeSH descriptor: [Anti-HIV Agents] explode all trees 3013
#9 MeSH descriptor: [Antiviral Agents] this term only 3778
#10 MeSH descriptor: [AIDS Vaccines] this term only 371
#11 anti hiv or antiretroviral* or anti retroviral* or AIDS vaccin* 7521
#12 #7 or #8 or #9 or #10 or #11 11280
#13 #6 and #12 7996
#14 MeSH descriptor: [Interleukin-2] explode all trees 848
#15 “interleukin 2”:ti,ab or IL2:ti,ab or IL-2:ti,ab aldesleukin:ti,ab
or proleukin:ti,ab or “interleukin II”:ti,ab or interleukin2:ti,ab
or “interleukine 2”:ti,ab (Word variations have been searched)
1526
#16 #14 or #15 1794
#17 #13 and #16 144
Appendix 2. MEDLINE search strategy
Date: 26 May 2016
Search Query Items found
#8 Search (#3 AND #4 AND #7) 634
#7 Search (#5 OR #6) 69303
#6 Search (interleukin 2[tiab] OR interleukin2[tiab] OR
IL2[tiab] OR IL-2[tiab] OR aldesleukin[tiab] OR pro-
leukin[tiab]OR interleukin II[tiab]OR interleukine 2[tiab])
62977
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(Continued)
#5 Search interleukin-2[mh] 36542
#4 Search (randomized controlled trial [pt] OR controlled clin-
ical trial [pt] OR randomized [tiab] OR placebo [tiab] OR
drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR
groups [tiab]) NOT (animals [mh] NOT humans [mh])
3285304
#3 Search (#1 AND #2) 99540
#2 Search (antiretroviral therapy, highly active[MeSH]OR anti-
retroviral agents[MeSH]ORantiviral agents[MeSH:NoExp]
OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab]
OR ((anti[tiab]) AND (retroviral*[tiab])) ORHAART[tiab]
OR ((anti[tiab]) AND (acquired immunodeficiency[tiab]))
OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab]))
OR ((anti[tiab]) AND (acquired immune-deficiency[tiab]))
OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (de-
ficiency[tiab]))
157998
#1 Search (HIV Infections[MeSH] OR HIV[MeSH] OR
hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab]
OR hiv2[tiab] OR hiv infect*[tiab] OR human im-
munodeficiency virus[tiab] OR human immunedeficiency
virus[tiab] OR human immuno-deficiency virus[tiab] OR
human immune-deficiency virus[tiab] OR ((human im-
mun*[tiab]) AND (deficiency virus[tiab])) OR acquired im-
munodeficiency syndrome[tiab] OR acquired immunede-
ficiency syndrome[tiab] OR acquired immuno-deficiency
syndrome[tiab] OR acquired immune-deficiency syn-
drome[tiab] OR ((acquired immun*[tiab]) AND (deficiency
syndrome[tiab])) OR “sexually transmitted diseases, Vi-
ral”[MeSH:NoExp])
344877
Appendix 3. Embase search strategy
Date: 26 May 2016
No. Query Results
#11 #3 AND #9 AND #10 318
#10 ’interleukin 2’/synOR interleukin2:ab,ti OR ’aldesleukin’/syn
OR ’proleukin’/syn OR il2 OR ’il+2’/syn OR ’interleukin ii’/
syn OR ’interleukine 2’
117687
#9 #4 NOT #8 1615894
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(Continued)
#8 #5 NOT #7 5350278
#7 #5 AND #6 1470137
#6 ’human’/de OR ’normal human’/de OR ’human cell’/de 17154813
#5 ’animal’/de OR ’animal experiment’/de OR ’invertebrate’/de
OR ’animal tissue’/de OR ’animal cell’/de OR ’nonhuman’/
de
6820415
#4 ’randomized controlled trial’/de OR ’randomized controlled
trial’ OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR fac-
torial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volun-
teer*:ab,ti OR ’crossover procedure’/de OR ’crossover proce-
dure’ OR ’double-blind procedure’/de OR ’double-blind pro-
cedure’ OR ’single-blind procedure’/de OR ’single-blind pro-
cedure’ OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti
AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti
OR (cross NEXT/1 over*):ab,ti
1811081
#3 #1 AND #2 140652
#2 ’human immunodeficiency virus vaccine’/expOR ’human im-
munodeficiency virus vaccine’ OR ’human immunodeficiency
virus vaccine’:ab,ti OR ’anti human immunedeficiency’:ab,ti
OR ’anti human immunodeficiency’:ab,tiOR ’anti human im-
muno-deficiency’:ab,ti OR ’anti human immune-deficiency’:
ab,ti OR ’anti acquired immune-deficiency’:ab,ti OR ’anti ac-
quired immunedeficiency’:ab,tiOR ’anti acquired immunode-
ficiency’:ab,ti OR ’anti acquired immuno-deficiency’:ab,ti OR
’anti hiv’:ab,ti OR antiretrovir*:ab,ti OR ’anti retroviral’:ab,ti
OR ’anti retrovirals’:ab,ti OR ’anti retrovirus’:ab,ti OR haart:
ab,ti OR ’aids vaccine’:ab,ti OR ’aids vaccines’:ab,ti OR ’anti
human immunodeficiency virus agent’/exp OR ’anti human
immunodeficiency virus agent’ OR ’anti human immunodefi-
ciency virus agent’:ab,ti OR ’antiretrovirus agent’/expOR ’an-
tiretrovirus agent’ OR ’antiretrovirus agent’:ab,ti OR ’highly
active antiretroviral therapy’/exp OR ’highly active antiretro-
viral therapy’ OR ’highly active antiretroviral therapy’:ab,ti
196031
#1 ’human immunodeficiency virus infection’/exp OR ’human
immunodeficiency virus infection’/de OR ’human immun-
odeficiency virus infection’ OR ’human immunodeficiency
virus’/exp OR ’human immunodeficiency virus’/de OR ’hu-
man immunodeficiency virus’ OR ’human immunodeficiency
virus:ab,ti’ OR hiv:ab,ti OR ’hiv-1’:ab,ti OR ’hiv-2’:ab,ti OR
’human immunodeficiency virus’:ab,ti OR ’human immuned-
eficiency virus’:ab,ti OR ’human immune-deficiency virus’:ab,
ti OR ’human immuno-deficiency virus’:ab,ti OR ’acquired
446717
66Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
immunodeficiency syndrome’:ab,ti OR ’acquired immuno-
deficiency syndrome’:ab,ti OR ’acquired immune-deficiency
syndrome’:ab,ti OR ’acquired immunedeficiency syndrome’:
ab,ti
Appendix 4. ClinicalTrials.gov search strategy
Search strategy: HIV AND (“interleukin-2” OR “interleukin 2” OR aldesleukin OR proleukin OR “interleukin II”) | Interventional
Studies | received from 11/14/2014 to 05/26/2016
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MeSH check words
Adult; Humans
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